BrainStorm Cell Therapeutics Inc. is a clinical-stage biotechnological company developing innovative, adult stem cell therapeutic products, derived from autologous bone marrow cells, for the treatment of highly debilitating neurodegenerative disorders. The company's current primary targets are Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease) and Parkinson?s disease (PD). These devastating diseases have no treatment options and as such represent highly unmet medical needs. Upon completion of BrainStorm?s clinical trials program and regulatory approvals, this novel therapy will provide compelling medical and economic benefits for patients, medical practitioners, and insurance/healthcare providers. By redirecting the inherent regenerative capacities of adult stem cells towards treating the basic disease pathologies, BrainStorm will enable healthcare institutions and society at large to realize massive savings in treatment and care costs. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of the Tel-Aviv University.